Indian injectables maker KriGen to build $7M plant in North Carolina

B. Braun IV bags
KriGen Pharmaceuticals, an India-based injectables maker, unveiled plans to build a $7 million facility in Lillinton, North Carolina. (B.Braun)

KriGen Pharmaceuticals, an India-based injectables maker, unveiled plans to build a $7 million facility in Lillington, North Carolina.

The 55,000-square-foot facility will produce medical IV bags and injectables and create about 100 jobs. According to the company’s website, KriGen products currently include dextrose and sodium chloride IV bags.

“The vision of KriGen Pharmaceuticals is to improve the quality of human lives by providing affordable pharmaceutical formulations based on innovation and technology,” Dhruvkumar Patel, the company’s chief financial officer, said in a statement reported by WRAL TechWire.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

The company is expected to receive a $200,000 grant from the One North Carolina Fund as part of an effort to attract KriGen to the state.

The company did not say when the project is expected to be completed.

A saline shortage due to production issues with a number of manufacturers since 2014 was exacerbated when hurricanes Irma and Maria wreaked havoc on pharma plants in Puerto Rico.

Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.

Amidst a gung-ho shift to oncology, Daiichi is also fleshing out its gene therapy capacity with a $200 million licensing deal with Ultragenyx.